Why is Rentokil Initial stock sliding today?

Rentokil Initial ADR stock experienced a 3.1% decline in early trading, hitting a new 52-week low of $19.86. The significant drop was triggered by Morgan Stanley's decision to downgrade the shares from Overweight to Equal Weight, along with a 16% reduction in its price target from GBP 5.00 to GBP 4.20. This move was primarily driven by mounting competitive pressure in the U.S. pest control market and shrinking peer valuation multiples.

Morgan Stanley's analysts pointed out that private equity-backed operators have rapidly expanded their presence in the U.S. market, now representing over 16% of revenue among the top 100 pest control companies, up from a mere 1% a decade ago. This expansion is putting pressure on Rentokil and its main rival, Rollins. The bank further noted that it does not anticipate Rentokil returning to its previous premium earnings multiple and expects a weak third-quarter report, with a full turnaround under the new chief executive likely to be a protracted process.

Notably, Morgan Stanley maintained its Overweight rating on Rollins, indicating a preference for the competitor over Rentokil at present. The downgrade comes at a challenging time for Rentokil, as its shares have already declined by more than 30% since June and were trading at historically low valuation multiples prior to today's session.

The company's earlier announcement of retiring its 2027 North America margin target of 20% had already dampened investor confidence. Additionally, hedge fund ownership in the stock fell from 19 portfolios to 15 in the most recent quarter. While the broader U.S. equity markets provided little respite, with the S&P 500 down 0.4%, the Dow Jones down 0.7%, and the Nasdaq off 0.2%, the combination of a high-profile analyst downgrade, a substantially reduced price target, structural competitive headwinds in Rentokil's key growth market, and a weak macro backdrop culminated in pushing the ADR to its lowest point in 52 weeks.